Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ketasyn: Phase IIa data

In a double-blind, U.S. Phase IIa trial in 159 patients with age-associated

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE